Using gene transfer technologies to reprogram adult human kidney cells could lead to novel therapies for chronic kidney disease.

Preventing the formation of secretory structures that promote scarring in the kidney could offer new therapeutic options for a disease that affects millions of people worldwide.

Activation of the signaling protein YAP may be a target for treating acute kidney injury, which affects up to 20 percent of hospitalized patients.

Treatment of anemia caused by chronic kidney disease or other diseases often requires repeated — and costly — injections or infusions of an artificial form of the hormone erythropoietin (EPO), which stimulates production of red blood cells.

Making multiple measurements with MRI can provide comprehensive information about the molecular and cellular changes caused by kidney injury.

New research by Vanderbilt nephrologists highlights potential barriers that may prevent black Americans from being screened for kidney disease.

Vanderbilt investigators have developed a new mouse model of kidney fibrosis, which provides a platform for identifying new targets and treatment strategies.